Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to match standard care in colorectal cancer battle

NCT ID NCT07595276

Not yet recruiting Disease control Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tests whether a new drug called Enlituo, combined with chemotherapy (FOLFOX), works as well as the standard treatment Erbitux plus FOLFOX for people with advanced colorectal cancer that has specific genetic traits (RAS/BRAF wild-type and MSS/pMMR). About 608 adults will receive one of the two treatments every two weeks. The main goal is to see how many patients' tumors shrink within 16 weeks. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••